…and some to hold, avoid or sell

AstraZeneca

Investors Chronicle

The pharma giant’s recent trial of an immune-oncology therapy for advanced lung cancer showed no better survival rates than chemotherapy treatment. Shares trade at a premium. Sell. £73.37.

Eddie Stobart Logistics

Investors Chronicle

After a review of the firm’s accounting practices, the CEO has quit and the shares have been suspended. Profits will be “significantly” below expectations, and the market may not be kind when trading resumes. Sell. 71p.

Naked Wines

The Times

The retailer is selling Majestic to focus on its growing online business Naked, which produces 1,000 wines from 17 countries. But it “eats up” investment capital, shares are volatile and margins are heavily squeezed. Avoid. 263p.

The Times

Sirius shares dived on news of the suspension of a $500m bond, which is needed to access a $2.5bn credit facility to get the Yorkshire potash mine up and running. But there’s still a chance it can raise the money. Hold. 9.25p.

Sportech

Investors Chronicle

The digital betting firm has overhauled its management team and slashed costs. But shares have lost half their value in twelve months, and it is struggling to make headway in the US. Hold. 32p.

Investors Chronicle

This highly acquisitive floor-coverings specialist has suffered two profit warnings, rising raw material prices and an unsuccessful attempt to refinance its soaring debt. More clarity in reporting is needed. Sell. 490p.